Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy

• Published in: iScience Vol. 23; no. 9; p. 101453
• Main Authors: Sperry, Jantzen, Condro, Michael C., Guo, Lea, Braas, Daniel, Vanderveer-Harris, Nathan, Kim, Kristen K.O., Pope, Whitney B., Divakaruni, Ajit S., Lai, Albert, Christofk, Heather, Castro, Maria G., Lowenstein, Pedro R., Le Belle, Janel E., Kornblum, Harley I.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 25.09.2020; Elsevier
• Subjects: Cancer; Diet; Pathophysiology; Pathophysiology; Diet; Cancer
• ISSN: 2589-0042; 2589-0042
• DOI: 10.1016/j.isci.2020.101453

Glioblastoma (GBM) metabolism has traditionally been characterized by a primary dependence on aerobic glycolysis, prompting the use of the ketogenic diet (KD) as a potential therapy. In this study we evaluated the effectiveness of the KD in GBM and assessed the role of fatty acid oxidation (FAO) in promoting GBM propagation. In vitro assays revealed FA utilization throughout the GBM metabolome and growth inhibition in nearly every cell line in a broad spectrum of patient-derived glioma cells treated with FAO inhibitors. In vivo assessments revealed that knockdown of carnitine palmitoyltransferase 1A (CPT1A), the rate-limiting enzyme for FAO, reduced the rate of tumor growth and increased survival. However, the unrestricted ketogenic diet did not reduce tumor growth and for some models significantly reduced survival. Altogether, these data highlight important roles for FA and ketone body metabolism that could serve to improve targeted therapies in GBM. [Display omitted] •Glioblastoma cells can use fatty acid oxidation and ketones for energy requirements•Inhibition of fatty acid oxidation reduces glioblastoma growth in vivo and in vitro•Unrestricted ketogenic diet does not reduce tumor growth in multiple models of GBM•IDH1 mutant glioblastomas may use FAO differently than IDH wild-type tumors Pathophysiology; Cancer; Diet